Find out more about Allergan’s presbyopia drop NDA filing


Potential presbyopia treatment coming

Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.

Click here to read this interview's transcript

Click here to listen to this interview's podcast

Related Videos
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
© 2023 MJH Life Sciences

All rights reserved.